For children with severe hypertrophic cardiomyopathy caused by gain-of-function RAS/mitogen-activated protein kinase ( ...

A study reveals that a personalized approach, considering age, sex and size, improves the diagnosis of hypertrophic ...

Trametinib, a mitogen-activated protein kinase (MEK) inhibitor, reduces mortality and morbidity in children with severe ...

The couple fled their neighborhood in Altadena last Tuesday night for a friend’s guest house in Toluca Lake. The next day, ...

Tenaya plans to present data from its pediatric non-interventional natural history study, known as MyClimb, in the second ...

Trametinib is a mitogen-activated protein kinase (MEK) inhibitor and the research findings are published in JACC: Basic to Translational Science highlights the urgent medical assistance for ...

An initiative to improve care and standardize identification, assessment, referrals, and treatment for patients with HCM has been launched by the AHA.

Trametinib, a mitogen-activated protein kinase (MEK) inhibitor, reduces mortality and morbidity in children with severe hypertrophic cardiomyopathy (HCM) caused by pathogenic variants in the RAS ...

Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today provided recent corporate updates and highlighted upcoming priorities for 2025. Edgewise Chief ...

WOMEN are missing out on diagnosis of a potentially deadly heart condition which affects one in 500 people, says new research ...